RxDoctor Payments Data

David Lazar, MD

Retina Specialist · Los Angeles, CANPI 1417242975

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,679 of the $9,047 with a category attached, or 73.8%. 29 manufacturers reported payments, led by Dutch Ophthalmic, USA at 27.6% of the total. Reporting peaked in 2022 at $3,446 and has fallen 75.3% since, to $852 in 2025.

$9,047in general payments, 2019–2025

Across 113 payments — averaging $80.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dutch Ophthalmic, USA$2K
  • Glaukos Corporation$876
  • Optos, Inc.$859
  • Regeneron Healthcare Solutions, Inc.$732
  • Novartis$629
  • AbbVie$491
  • plus $3K from 23 others
$12,677in research payments, 2019–2025

Across 2 payments — averaging $6338.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$13K

What the payments were for

  • Consulting fees$2,25025%
  • Food & beverage$6,67974%
  • Entertainment$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,047 in reported general payments places this provider in the 65th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$1,559,060
Medicare patients
861
Services billed
6,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate44$1,498
Ofloxacin17$330
Latanoprost16$95
Azelastine Hcl11$84
Timolol Maleate12$63

Paid to pharmacies, not to this prescriber.

Other retina specialist in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →